The STC2 (stanniocalcin-2) antibody is a tool used to study the STC2 protein, a glycoprotein hormone involved in calcium-phosphate homeostasis, cell proliferation, apoptosis, and metabolic regulation. STC2. part of the stanniocalcin family, is expressed in various tissues and has been implicated in cancer progression, fibrosis, and inflammatory diseases. Its dual role as both oncogenic and tumor-suppressive in different contexts makes it a complex therapeutic target.
STC2 antibodies are essential for detecting and quantifying STC2 expression in research, diagnostics, and drug development. They enable techniques like Western blotting, immunohistochemistry, and ELISA to explore STC2's tissue distribution, overexpression in tumors (e.g., breast, lung, colorectal cancers), and association with poor prognosis. Recent studies also highlight STC2's role in stress responses, such as hypoxia and endoplasmic reticulum stress, linking it to adaptive cellular mechanisms.
Despite progress, challenges remain in standardizing antibody specificity and understanding STC2's precise molecular pathways. Ongoing research aims to clarify its therapeutic potential, particularly in targeting cancer metastasis or metabolic disorders. STC2 antibodies thus serve as critical reagents for unraveling its biological complexity and translational applications.